secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0000950170-24-138419
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio doses first patient in Phase 1 trial of ADI-270 for advanced clear cell renal cell carcinoma
--------------------------------------------------------------------------------

- First patient dosed in Phase 1 trial of ADI-270, an allogeneic gamma delta 1 CAR T cell therapy, for metastatic/advanced ccRCC.
- Phase 1 trial is multicenter, open-label, monotherapy; starting dose 3E8 CAR+ cells with option for second dose.
- Company expects to report preliminary Phase 1 clinical data in the first half of 2025.
- Preclinical data showed ADI-270 demonstrated tumor infiltration, resistance to immunosuppressive TME, and potent CAR/innate activity.
- ccRCC is the most common kidney cancer; patients with advanced disease have limited treatment options and high unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024138419/0000950170-24-138419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024138419/acet-20241219.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-138419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer